WO2024249489A1 - Container closure with reverse coefficient of thermal expansion materials - Google Patents
Container closure with reverse coefficient of thermal expansion materials Download PDFInfo
- Publication number
- WO2024249489A1 WO2024249489A1 PCT/US2024/031431 US2024031431W WO2024249489A1 WO 2024249489 A1 WO2024249489 A1 WO 2024249489A1 US 2024031431 W US2024031431 W US 2024031431W WO 2024249489 A1 WO2024249489 A1 WO 2024249489A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- syringe
- stopper
- barrel
- distal end
- thermal expansion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
- A61M5/31513—Piston constructions to improve sealing or sliding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3103—Leak prevention means for distal end of syringes, i.e. syringe end for mounting a needle
- A61M2005/3104—Caps for syringes without needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3103—Leak prevention means for distal end of syringes, i.e. syringe end for mounting a needle
- A61M2005/3106—Plugs for syringes without needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
Definitions
- the present disclosure relates generally to closure containers such as prefilled syringes and, more particularly, to a sealing component for use with a prefilled syringe that exhibits minimal shrinkage and/or possible expansion at low temperatures, so as to preserve the closure integrity of the syringe liquid content during transport or storage.
- Closure containers are used in the medical field for storing and potentially dispensing fluids, such as medications or drugs.
- the closure container is provided as a stoppered glass or plastic container (e.g., glass or plastic vial or syringe) with an elastomeric closure.
- the medication or drug stored in the closure container may include, for example, vaccines or cell therapies.
- the syringe When a closure container is provided as a prefilled syringe for dispensing fluids, the syringe will typically include a syringe barrel with an opening at a distal end and a plunger assembly inserted through the opposite proximal end of the barrel.
- the plunger assembly typically includes an elongated plunger rod extending out of the barrel, and a plunger head or stopper disposed at the distal end of the plunger rod.
- the stopper or plunger stopper is typically made of elastomeric material, and comprises a body with a tail disposed at its proximal end adapted for attachment to the distal end of the plunger rod, and a head disposed at its distal end.
- On an external cylindrical wall of the body is defined a plurality of annular outwardly protruding ribs adapted to ensure the container closure integrity of a syringe when the stopper is inserted into the syringe.
- the opening of the syringe barrel on the distal end is adapted for fluid communication with a patient, such as through a needle already attached to the syringe barrel (stacked needle syringe barrel), or through a hypodermic needle fitted at the distal end of the syringe barrel (Luer syringe barrel), or through a Luer-type fitting (needleless access device) fitted at the distal end of the syringe barrel and connected to a fluid line of a patient.
- a needle already attached to the syringe barrel stacked needle syringe barrel
- a hypodermic needle fitted at the distal end of the syringe barrel
- Luer-type fitting needleless access device
- Prefilled syringes provide the convenience of rapidly delivering the content to a patient without the need to first aspirate the medication from another container and meter its volume. At the same time, there is a need to maintain sterility and container closure integrity of the medication inside the prefilled syringe, including over an extended period of time, and throughout exposure to various storage and transport conditions. In some circumstances, prefilled syringes are subjected to extremely cold temperatures - including temperatures down to as low as -80 to -196°C (i.e., liquid nitrogen temperature) - in order to properly store the medication contained therein (e.g., a vaccine or cell therapy).
- extremely cold temperatures including temperatures down to as low as -80 to -196°C (i.e., liquid nitrogen temperature) - in order to properly store the medication contained therein (e.g., a vaccine or cell therapy).
- prefilled syringes are subjected to a combination of cold temperatures and higher pressures, such as when being transported on a plane, for example. Maintaining container closure integrity in these conditions is a big challenge for prefilled syringes based, at least in part, on the coefficient of thermal expansion (CTE) mismatch between the stopper and the barrel materials.
- CTE coefficient of thermal expansion
- this level of CTE mismatch may result in an interference rate between the stopper and the barrel dropping by approximately 30% - this being due at least in part to the elastomeric stopper being brought to its glass transition temperature (Tg) where the elastic properties of the stopper are altered so that it becomes “glass-like” and loses its ability to apply a strong contact pressure against the barrel and maintain a seal therewith.
- Tg glass transition temperature
- Any contact pressure variation/reduction between the stopper and barrel during the thermal cycle may present risk on the container closure integrity either by creating a leaking channel (partial lack of contact) at the barrel-stopper interface and/or by enabling stopper movement inside the barrel during the freeze-thaw cycles.
- a large CTE mismatch between the barrel and the stopper can also cause issues with subsequent container closure integrity when initially inserting the stopper into the barrel. That is, during initial assembly of a pre-filled syringe, a stopper is typically placed by using vent tube stoppering, which consists in compressing the stopper (using a vent tube stoppering tool) to have a diameter significantly smaller than the barrel internal diameter, before placing the stopper into the barrel and allowing the stopper to expand back and become sealed in the barrel.
- vent tube stoppering which consists in compressing the stopper (using a vent tube stoppering tool) to have a diameter significantly smaller than the barrel internal diameter, before placing the stopper into the barrel and allowing the stopper to expand back and become sealed in the barrel.
- vent tube stoppering which consists in compressing the stopper (using a vent tube stoppering tool) to have a diameter significantly smaller than the barrel internal diameter, before placing the stopper into the barrel and allowing the stopper to expand back and become sealed in the barrel.
- closure containers including prefilled syringes, that are able to maintain sterility and container closure integrity even at extremely low cold storage temperatures.
- a need further exists for a method of manufacturing such closure containers that maintains container closure integrity throughout and subsequent to such manufacturing.
- a prefilled syringe including a syringe barrel having a proximal end and a distal end and defining a chamber, the syringe barrel having an opening at the proximal end.
- the prefilled syringe also includes a plunger assembly inserted through the opening and axially movable within the chamber of the syringe barrel, with the plunger assembly further including a plunger rod having an elongated body extending between a proximal end and a distal end and a stopper attached to the distal end of plunger rod and positioned within the barrel chamber.
- the stopper is composed of a blended material including an elastomeric material and an intermixed material having a coefficient of thermal expansion lower than the elastomeric material.
- the intermixed material has a negative coefficient of thermal expansion.
- the blended material of the stopper has a coefficient of thermal expansion matching a coefficient of thermal expansion of the syringe barrel or lower than the coefficient of thermal expansion of the syringe barrel.
- the stopper is configured to expand at room temperature or at cold storage temperatures of 0°C and lower, so as to maintain a closure integrity between the stopper and the syringe barrel.
- the intermixed material is graphene, a hexagonal boron nitride compound (coronene), ScF3 compound, ZrW2O8, or beta-eucryptite and Ca2RuO4.
- the stopper includes an inert coating applied to at least a portion of an outer surface thereof.
- the inert coating is a parylene coating.
- the syringe barrel is composed of a glass substrate.
- the syringe barrel is composed of a polymeric substrate.
- the stopper is a molded stopper formed via molding of a blend of the elastomeric material and the intermixed material.
- the syringe includes a distal end cap positioned over a nozzle at the distal end of the barrel chamber, wherein the distal end cap is composed of a blended material including a polymeric material and an intermixed material having a coefficient of thermal expansion lower than the polymeric material.
- the apparatus includes a container having a proximal end and a distal end and defining a chamber, with the container having an opening at the proximal end.
- the apparatus also includes a sealing component positioned at least partially within the chamber such that at least a portion of the sealing component forms an interference fit with the container, wherein the sealing component is composed of a blended material including an elastomeric material and an intermixed material having a coefficient of thermal expansion lower than the elastomeric material.
- the intermixed material has a negative coefficient of thermal expansion (NCTE).
- the intermixed material is graphene, hexagonal boron nitride (coronene) compound, ScF3 compound, ZrW2O8, or beta-eucryptite and Ca2RuO4.
- the stopper includes an inert coating applied to at least a portion of an outer surface thereof.
- the container is composed of one of a glass substrate and a polymeric substrate.
- the apparatus is a prefilled syringe, with the container being a syringe barrel and the sealing component being a stopper affixed to a distal end of a plunger rod.
- the apparatus includes a distal end cap positioned over a nozzle at the distal end of the chamber, and wherein the distal end cap comprises a blended material including another polymeric material and an intermixed material having a coefficient of thermal expansion lower than the polymeric material.
- a method of assembling a prefilled syringe includes providing a syringe barrel comprising a proximal end and a distal end and defining a chamber, the syringe barrel having an opening at the proximal end.
- the method also includes providing a plunger assembly insertable into the opening, the plunger assembly including a plunger rod comprising an elongated body and extending between a proximal end and a distal end and a stopper attached to the distal end of plunger rod and positioned within the barrel chamber, wherein the stopper comprises a blended material including an elastomeric material and an intermixed material having a negative coefficient of thermal expansion that is lower than a coefficient of thermal expansion the elastomeric material.
- the method further includes heating a vent tube stoppering tool that holds the plunger assembly therein, with the vent tube stoppering tool heated to a temperature that causes the stopper to contract, due to the intermixed material with the negative coefficient of thermal expansion, and inserting the plunger assembly into the syringe barrel using the vent tube stoppering tool.
- the method also includes filling the barrel with a liquid solution prior to inserting of the plunger assembly.
- FIG. 1 is a perspective view of a prefilled syringe, according to a non-limiting embodiment described herein;
- FIG. 2 is an exploded view of the syringe of FIG. 1;
- FIG. 3 is a side cross-sectional view of the syringe of FIG. 1, with a plunger assembly thereof in an initial or pre-use position;
- FIG. 4 is a detailed view of a stopper positioned within a barrel of the syringe of FIG. 1;
- FIG. 5 is a cross-sectional view of a vial and associated sealing component, according to another non-limiting embodiment described herein.
- the distal end of a component or of a device means the end furthest away from the hand of the user and the proximal end means the end closest to the hand of the user, when the component or device is in the use position, i.e., when the user is holding a syringe in preparation for or during use.
- the terms “in the distal direction” and “distally” mean in the direction toward the distal tip of the syringe
- the terms “in the proximal direction” and “proximally” mean in the direction opposite the direction of the distal tip of the syringe.
- aspects and embodiments of the disclosure are directed to the use of low or negative coefficient of thermal expansion (NCTE) materials in a container closure or sealing component.
- the use of the low or negative CTE material allows for a sealing component to have a CTE more closely matched to the CTE of the container in which it is seated.
- the sealing component may be configured to expand when a container is exposed to cold storage temperatures.
- the syringe 10 generally includes a syringe barrel 12 and a plunger assembly 14.
- the plunger assembly 14 is axially movable within the syringe barrel 12 to an advanced position to facilitate administering of an injectable fluid (e.g., medication) to a patient, for example.
- an injectable fluid e.g., medication
- the syringe barrel 12 is formed of a generally cylindrical outer wall 16 and an end wall 18 that collectively define a chamber 20 for retaining fluid therein.
- the syringe barrel 12 includes an open proximal end 22 configured to receive the plunger assembly 14 therein and a distal end 24 at which end wall 18 is positioned.
- the proximal end 22 of the syringe barrel 12 may include a flange 26 to facilitate handling and positioning of the syringe 10 and to maintain the relative position of the syringe barrel 12 with respect to the plunger assembly 14 during medication administration.
- the distal end 24 of syringe barrel 12 may include a tip 28 that extends distally outward from the end wall 18 and defines a lumen 30 in fluid communication with the chamber 20.
- a luer lock adapter 29 is mounted on an external surface of the tip 28 that is coupleable to a rigid cap 31 that covers the tip 28 and/or to a corresponding needle hub (not shown) to which the syringe 10 is to be brought into engagement for administering fluid to a patient.
- the adapter 29 comprises a cylindrical body having a threaded inner surface that is configured to engage an outer surface of a threaded portion of the rigid cap 31.
- syringe 10 may be provided as a staked needle syringe, where a needle is secured to syringe barrel 12 and extends out distally therefrom, with a needle shield positioned over the needle.
- the rigid cap 31 may be configured as a rigid cap that mates with the adapter 29, so as to provide a fluid-tight seal over the tip 28, with a proximal end of the rigid cap 31 configured to engage the adapter 29 and a distal end configured as a closed end, with some embodiments of rigid cap 31 including an elastomeric inner cap 33 (“RiTC”) positioned in the rigid cap 31 so as to cover the tip 28 and be partially inserted into lumen 30 of tip 28.
- RiTC elastomeric inner cap 33
- the plunger assembly 14 of syringe 10 is formed of an elongate plunger rod 32 (more generally “plunger 32,” as used hereafter) and a plunger head or stopper 34.
- the plunger 32 may include a main body 36 extending between a plunger proximal end 38 and a plunger distal end 40.
- the main body 36 may include a plurality of elongate vanes or walls 42 extending axially along a length thereof between the plunger proximal end 38 and the plunger distal end 40.
- a thumb press 44 is positioned at the plunger proximal end 38 that may be engaged by a thumb (or other finger) of the user to apply a distally directed force to the plunger assembly 14 to move the plunger 32 with respect to the syringe barrel 12.
- a flanged extension member 46 e.g., disc-shaped flange
- the plunger distal end 40 may include a female receptacle formed therein that is configured to receive and connect to a protrusion (e.g., pin) extending out proximally from the stopper, with the protrusion and receptacle engaging via threading, for example.
- the stopper 34 of plunger assembly 14 is positioned at the plunger distal end 40 so as to be movable along with the plunger 32 within the chamber 20 of syringe barrel 12.
- the stopper 34 may be made from a material that is different from the material of the plunger 32 and that is capable of forming a tight seal with the syringe barrel 12 as it is advanced therethrough.
- the stopper 34 includes a receptacle 56 (FIG.
- the attachment member 48 may further include a pair of spacedapart annular flanges 58 formed thereon (i.e., O-rings) that form a tight seal with the cylindrical outer wall 16 of syringe barrel 12.
- syringe 10 may be provided as a prefilled syringe, such that the syringe 10 contains a drug or medication prefilled within chamber 20.
- the drug or medication within the chamber 20 of prefilled syringe 10 may be a drug or medication that requires cold storage (i.e., cryogenic storage) at temperatures down to as low as -80 to -196°C.
- cryogenic storage i.e., cryogenic storage
- the syringe 10 may thus be specifically configured to maintain sterility and container closure integrity at cold storage temperatures.
- an interference rate between the stopper 34 and the barrel 12 may be maintained even down at extremely low cold storage temperatures where an elastomeric material of the stopper 34 is brought to its glass transition temperature (Tg).
- the stopper 34 is formed of a flexible, elastomeric material 60 mixed with another (intermixed) material 62 having a CTE that is less than the CTE of the elastomeric material and, in some embodiments, has a negative CTE at the storage temperature, which may be below 0°C and down to as low as -80 to -196°C.
- the intermixed material 62 is preferably interspersed with the elastomeric material 60 in a manner that will counter contraction of the elastomeric material 60 when the elastomer is near or goes below the Tg of the elastomer, thus allowing for the stopper 34 to maintain contact pressure with the barrel 12.
- the syringe 10 may have a centerline axis 64, wherein the barrel 12 and stopper 34 are coaxial along the centerline axis 64 when assembled, and when the syringe 10 is stored at low temperatures, such as cryogenic temperatures, the elastomeric material 60 of the stopper 34 may contract radially towards the centerline axis 64; however, the intermixed material 62 having a lower coefficient of thermal expansion preferably contracts less, or more preferably, may expand radially away from centerline axis 64 if the CTE of the intermixed material 62 is negative at the storage temperature.
- the amount of the intermixed material 62 incorporated into the stopper 34 is dependent on the difference between the CTEs of the intermixed material 62 and elastomeric material 60 and/or on the CTE of the substrate material from which the barrel 12 is formed (e.g., glass or a polymeric material). For example, if the intermixed material 62 has a CTE that is much less than the CTE of the elastomeric material 60, then more of the intermixed material 62 may be required to attain the desired counter- action of the expected contraction of the elastomeric material 60 and/or to achieve a negative CTE for the overall stopper 34.
- the difference between the CTEs between the two materials is small, a lesser amount of the intermixed material 62 may be required to achieve the same degree of resistance to the contraction of the elastomeric material 60 and/or to configure the stopper 34 to expand at a low temperature.
- Examples of the elastomeric material 60 for forming the stepper according to the various embodiments of the present disclosure include, but are not limited to, synthetic or natural rubbers, such as butyl rubber, isoprene rubber, butadiene rubber, halogenated butyl rubber (e.g., bromobutyl rubber), ethylene propylene terpolymer, silicone rubber; combinations thereof and the like.
- the elastomeric material 60 is a butyl or halobutyl elastomer.
- the elastomeric material 60 may further comprise one or more additives such as a vulcanizing agent, a vulcanizing accelerator, a vulcanizing activator, a processing aid, a filler, and a reinforcing agent to improve or enhance the properties of the elastomeric material 60.
- additives such as a vulcanizing agent, a vulcanizing accelerator, a vulcanizing activator, a processing aid, a filler, and a reinforcing agent to improve or enhance the properties of the elastomeric material 60.
- Examples of the intermixed material 62 included in the stopper 34 include, but are not limited to, graphene, hexagonal boron nitride (coronene) compounds, ScF3 , ceramic types such as zirconium ZrW2O8, or beta-eucryptite and Ca2RuO4, perovskite BiNiO3, and nano metal oxides like CuO.
- graphene hexagonal boron nitride (coronene) compounds
- ScF3 ceramic types such as zirconium ZrW2O8, or beta-eucryptite and Ca2RuO4, perovskite BiNiO3, and nano metal oxides like CuO.
- the stopper 34 is formed of a rubber-graphene blend, with a 0.1 to 19% graphene content.
- the amount of graphene or other NCTE materials may replace partially or totally typical rubber reinforcement materials like clays or silica.
- the stopper 34 could be a rubber blend with up to 40% of any of the NCTE compounds described above.
- the stopper 34 may be manufactured via a molding process, with the elastomeric material 60 and intermixed material 62 being blended together prior to molding. Upon blending of the materials, the stopper 34 may be molded under relative high temperatures (e.g., 120-190°C) to allow the cross linking of the molecules therein and obtaining of the elastic and resilience properties of the stopper 34.
- relative high temperatures e.g. 120-190°C
- the stopper 34 may be molded while avoiding scorching of the elastomeric material 60 therein, with the graphene providing improved functional performance of the stopper 34 by increasing uniformity of the rubber curing state and toughness, and lowering the CTE of the stopper 34, as previously described.
- the stopper 34 may also include a protective coating 66 on at least a portion thereof that prevents potential interaction between the intermixed material 62 with the drug or medication contained within the chamber 20 of barrel 12.
- the coating 66 preferably covers at least a portion of the outer surface of the stopper 34 that is most likely to contact the drug or medication within the barrel 12 and prevents the leaching of the intermixed material 62 into the drug or medication. While coating 66 is shown in FIG. 4 as being applied to only a bottom portion of stopper 34, the coating 66 may be to an entirety of the outer surface of the stopper 34, according to other embodiments.
- the coating 66 is an inert film, preferably a parylene or fluoropolymer coating. According to one embodiment, the coating is a parylene C coating. [0051] According to aspects or embodiments of the disclosure, it is recognized that when the intermixed material 62 selected to prevent the overall contraction of the stopper 34 at low temperatures (i.e., cryogenic temperatures) has a negative CTE, the intermixed material 62 may potentially jeopardize the container closure integrity if the syringe 10 is exposed to higher temperatures.
- the interference rate between the stopper 34 and the barrel 12 may drop below an acceptable amount if the temperature to which the stopper 34 is exposed becomes unacceptably high (e.g., exceeds 25°C), such that a leaking channel may form at the barrel-stopper interface and/or the stopper 34 may move inside the barrel 12. Accordingly, when blending a negative CTE intermixed material 62 with the elastomeric material 60, a maximum high temperature should be defined at which the syringe 10 should be kept below.
- the stopper 34 it is desirable for the stopper 34 to be designed such that the interference between the stopper 34 and the barrel 12 does not drop by more than 30% of the initial interference, which may be an interference of 0.35mm as an example, as this would potentially jeopardize the container closure integrity.
- the temperature at which interference drops by 30%, Tao% may be defined by: where T am b is the ambient temperature, SOD is the stopper outer diameter, BID is the barrel inner diameter, CTEs is the CTE of the stopper, and CTE g is the CTE of the (glass) barrel, with the above relationship assuming that the CTE is constant over an entire temperature range.
- stopper 34 While it is recognized that the exposing of stopper 34 to high temperatures during storage/transport can cause the interference rate between the stopper 34 and the barrel 12 to drop below an acceptable amount when the stopper 34 includes an intermixed material 62 with a negative CTE - thereby jeopardizing container closure integrity - it is further recognized that such high temperatures may be beneficial during initial assembly of a container or syringe 10. That is, a stopper 34 that includes an intermixed material 62 with a negative CTE can present advantages during assembly due to the dimensions of the stopper 34 shrinking at temperatures above room temperature.
- a vent tube stoppering tool used to insert the stopper 34 can be heated to facilitate the stopper insertion process, as heating of the tool causes dimensions of the stopper 34 to shrink, thus reducing the interference rate between the stopper 34 and vent tube stoppering tool - which lessens the chances of the stopper 34 (and/or a coating 66 thereon) becoming damaged during assembly, thereby ensuring a subsequent container closure integrity when the stopper 34 is inserted in the barrel 12.
- a method of assembling a prefilled syringe includes providing a syringe barrel, providing a plunger assembly insertable into the syringe barrel and that includes a stopper comprising a blended material including an elastomeric material and an intermixed material having a negative coefficient of thermal expansion that is lower than a coefficient of thermal expansion of the elastomeric material, heating the vent tube stoppering tool that holds the plunger assembly therein, with the vent tube stoppering tool heated to a temperature that causes the stopper to contract (e.g., above 25°C), and inserting the plunger assembly into the syringe barrel using the vent tube stoppering tool.
- the method can also include filling the barrel with a liquid solution prior to inserting of the plunger assembly.
- portions of the rigid cap 31 may also be composed in part of a low or negative CTE material.
- the inner cap 33 (or a rubber inner portion of a needle shield) may be formed of a blended material including an elastomeric material and intermixed material having a negative coefficient of thermal expansion that is lower than a coefficient of thermal expansion of the elastomeric material, such as previously described for stopper 34.
- the inner cap 33 may therefore be specifically configured to have a CTE that closely matches that of barrel 12 (i.e., of tip 28 of the barrel), such that closure of the tip 28 is ensured and the closure integrity of the syringe 10 maintained.
- rigid cap 31 may be formed of a blend of a rigid polymeric material and an intermixed material 62 having a low or negative CTE.
- the cap portion may be formed as a graphene based polymer nanocomposite, with graphene being mixed with any suitable polymeric material, including polypropylene or polyethylene, as non-limiting examples.
- the polymeric portion of the rigid cap 31 may therefore also be specifically configured to have a CTE that closely matches that of a glass barrel 12 (i.e., tip 28).
- FIG. 5 generally illustrates such an apparatus that includes a container (vial) 70 and a sealing element (vial stopper) 72, where the vial 70 may be constructed of glass or a polymeric material and the vial stopper 72 may be formed of a blend of elastomeric material and a material with a low or negative CTE, as described in detail above regarding the syringe 10 of FIGS. 1-4.
- a negative CTE material 62 such as graphene may be blended into an elastomeric material 60 to form the vial stopper 72, so as to counter contraction of the vial stopper 72.
- the elastomeric material 60 of the vial stopper 72 may contract radially inward and away from vial 70; however, the intermixed material 62 having a lower coefficient of thermal expansion preferably contracts less, or more preferably, may expand radially outward toward vial 70 if the CTE of the intermixed material 62 is negative at the storage temperature.
- embodiments of the invention thus provide a container closure or sealing component that includes low or negative coefficient of thermal expansion (CTE) materials intermixed with another material, such as an elastomeric material.
- CTE coefficient of thermal expansion
- another material such as an elastomeric material.
- the use of the low or negative CTE material allows for a sealing component to have a CTE more closely matched to the CTE of the container in which it is seated.
- the sealing component may be configured to expand when a container is exposed to cold storage temperatures, thereby further ensuring container closure integrity even as extreme low cold storage temperatures.
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202480025470.5A CN120936399A (en) | 2023-05-30 | 2024-05-29 | Container closure with materials having opposite coefficients of thermal expansion |
| EP24735787.4A EP4719542A1 (en) | 2023-05-30 | 2024-05-29 | Container closure with reverse coefficient of thermal expansion materials |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18/203,127 US20240399064A1 (en) | 2023-05-30 | 2023-05-30 | Container Closure with Reverse Coefficient of Thermal Expansion Materials |
| US18/203,127 | 2023-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024249489A1 true WO2024249489A1 (en) | 2024-12-05 |
Family
ID=91664080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2024/031431 Ceased WO2024249489A1 (en) | 2023-05-30 | 2024-05-29 | Container closure with reverse coefficient of thermal expansion materials |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240399064A1 (en) |
| EP (1) | EP4719542A1 (en) |
| CN (1) | CN120936399A (en) |
| WO (1) | WO2024249489A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180251376A1 (en) * | 2015-10-07 | 2018-09-06 | Nippon Chemical Industrial Co., Ltd. | Negative thermal expansion material and composite material comprising same |
| US20220401654A1 (en) * | 2013-10-28 | 2022-12-22 | Becton, Dickinson And Company | Leak-Free Stopper Having Low Breakloose and Sustaining Forces |
| US20230064423A1 (en) * | 2020-02-13 | 2023-03-02 | West Pharmaceutical Services, Inc. | Containment and delivery systems for cryogenic storage |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013167701A1 (en) * | 2012-05-09 | 2013-11-14 | Schreiner Group Gmbh & Co. Kg | Closure element for a receptacle |
| WO2019005072A1 (en) * | 2017-06-29 | 2019-01-03 | Regeneron Pharmaceuticals Inc. | DEVICES AND METHOD FOR OVERFILLING MEDICINE CONTAINERS |
-
2023
- 2023-05-30 US US18/203,127 patent/US20240399064A1/en active Pending
-
2024
- 2024-05-29 EP EP24735787.4A patent/EP4719542A1/en active Pending
- 2024-05-29 WO PCT/US2024/031431 patent/WO2024249489A1/en not_active Ceased
- 2024-05-29 CN CN202480025470.5A patent/CN120936399A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220401654A1 (en) * | 2013-10-28 | 2022-12-22 | Becton, Dickinson And Company | Leak-Free Stopper Having Low Breakloose and Sustaining Forces |
| US20180251376A1 (en) * | 2015-10-07 | 2018-09-06 | Nippon Chemical Industrial Co., Ltd. | Negative thermal expansion material and composite material comprising same |
| US20230064423A1 (en) * | 2020-02-13 | 2023-03-02 | West Pharmaceutical Services, Inc. | Containment and delivery systems for cryogenic storage |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4719542A1 (en) | 2026-04-08 |
| US20240399064A1 (en) | 2024-12-05 |
| CN120936399A (en) | 2025-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11690788B2 (en) | System for closed transfer of fluids | |
| US10052259B2 (en) | Seal system for cannula | |
| US10610647B2 (en) | Syringe assembly with pivoting plunger and integral tip guard | |
| KR102401509B1 (en) | Tip cap assembly for closing an injection system | |
| US6666852B2 (en) | Axially activated vial access adapter | |
| CN103917262B (en) | Syringes with double pivoting piston rods | |
| BR112015033068B1 (en) | SAFETY SYRINGE | |
| AU2020206879A1 (en) | System for lyophilizing, reconstituting, and delivering a medication, and related methods | |
| CN104056328B (en) | Cannula Sealing System | |
| US11419985B2 (en) | Medication injection device | |
| US20240399064A1 (en) | Container Closure with Reverse Coefficient of Thermal Expansion Materials | |
| US12514984B2 (en) | Syringe tip cap | |
| JP2025536511A (en) | Infusion systems and methods | |
| CN114585344B (en) | A connector for connecting a medical injection device and a container, and an assembly including the connector and the medical injection device. | |
| EP4316550B1 (en) | Tip cap assembly for an injection system | |
| CN121889183A (en) | Occlusion tool system and method for installing a distal loading stop within a syringe barrel | |
| JP2025536802A (en) | Closure integrity kit for prefilled syringes, retaining clips, and plunger rods | |
| WO2026063969A1 (en) | Syringe device for dispensing fluids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24735787 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2025570014 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2025570014 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2024735787 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2024735787 Country of ref document: EP Effective date: 20260102 |
|
| ENP | Entry into the national phase |
Ref document number: 2024735787 Country of ref document: EP Effective date: 20260102 |
|
| ENP | Entry into the national phase |
Ref document number: 2024735787 Country of ref document: EP Effective date: 20260102 |
|
| ENP | Entry into the national phase |
Ref document number: 2024735787 Country of ref document: EP Effective date: 20260102 |
|
| ENP | Entry into the national phase |
Ref document number: 2024735787 Country of ref document: EP Effective date: 20260102 |
|
| WWP | Wipo information: published in national office |
Ref document number: 2024735787 Country of ref document: EP |

